Khoshandam Mohadeseh, Soheili Zahra-Soheila, Hosseinkhani Saman, Samiee Shahram, Latifi-Navid Hamid, Ahmadieh Hamid, Soltaninejad Hossein, Jahangiri Babak
Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Department of Molecular Medicine, Institute of Medical Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran.
Transl Oncol. 2025 Jun;56:102400. doi: 10.1016/j.tranon.2025.102400. Epub 2025 Apr 28.
The inhibition of angiogenesis is a crucial therapeutic strategy in cancer treatment, as it limits tumor growth and metastasis. In this study, we investigate the anti-angiogenic potential of a novel htsFLT01/MiRGD nanocomplex, designed to target key angiogenesis markers in cancer. This nanocomplex integrates the anti-angiogenic fusion protein htsFLT01 with the MiRGD peptide to enhance its efficacy. Our findings demonstrate that htsFLT01/MiRGD effectively suppresses angiogenesis both in vitro and in vivo, particularly in breast cancer models. Histological and molecular analyses reveal a significant reduction in blood vessel formation, accompanied by structural changes in tumor tissue. Furthermore, the expression levels of key angiogenesis-related genes, including VEGF, VEGFR, and CD31, are markedly downregulated, highlighting the therapeutic potential of this nanocomplex. Beyond its anti-angiogenic effects, the treatment also induces apoptosis and inhibits tumor cell proliferation, reinforcing its role as a promising targeted therapy for angiogenesis-dependent malignancies. These results underscore the potential of htsFLT01/MiRGD in cancer treatment and pave the way for future clinical applications in anti-angiogenic therapies.
抑制血管生成是癌症治疗中的一种关键治疗策略，因为它能限制肿瘤生长和转移。在本研究中，我们研究了一种新型htsFLT01/MiRGD纳米复合物的抗血管生成潜力，该复合物旨在靶向癌症中的关键血管生成标志物。这种纳米复合物将抗血管生成融合蛋白htsFLT01与MiRGD肽整合在一起，以增强其疗效。我们的研究结果表明，htsFLT01/MiRGD在体外和体内均能有效抑制血管生成，尤其是在乳腺癌模型中。组织学和分子分析显示血管形成显著减少，同时肿瘤组织出现结构变化。此外，包括VEGF、VEGFR和CD31在内的关键血管生成相关基因的表达水平明显下调，突出了这种纳米复合物的治疗潜力。除了其抗血管生成作用外，该治疗还诱导细胞凋亡并抑制肿瘤细胞增殖，强化了其作为血管生成依赖性恶性肿瘤的一种有前景的靶向治疗方法的作用。这些结果强调了htsFLT01/MiRGD在癌症治疗中的潜力，并为抗血管生成疗法的未来临床应用铺平了道路。
